July 14, 2008 – Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced the publication of a study conducted by Cyclacel scientists showing synergistic activity between its investigational therapy seliciclib and multiple epidermal growth factor receptor (EGFR) inhibitors, including erlotinib (Tarceva®) in models of non-small cell lung cancer and the HER2 targeting agent, trastuzumab (Herceptin®) in models of breast cancer. These preclinical results were published in the July issue of the journal, Clinical Cancer Research. Seliciclib, Cyclacel’s orally available cyclin dependent kinase (CDK) inhibitor, is currently being tested as a single agent in the Phase 2b APPRAISE trial in patients with non-small cell lung cancer and in a Phase 2 study in patients with nasopharyngeal cancer... Cyclacel's Press Release -
Jul 15, 2008
Cyclacel : study of seliciclib synergy with Tarceva and Herceptin in journal Clinical Cancer Research
July 14, 2008 – Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced the publication of a study conducted by Cyclacel scientists showing synergistic activity between its investigational therapy seliciclib and multiple epidermal growth factor receptor (EGFR) inhibitors, including erlotinib (Tarceva®) in models of non-small cell lung cancer and the HER2 targeting agent, trastuzumab (Herceptin®) in models of breast cancer. These preclinical results were published in the July issue of the journal, Clinical Cancer Research. Seliciclib, Cyclacel’s orally available cyclin dependent kinase (CDK) inhibitor, is currently being tested as a single agent in the Phase 2b APPRAISE trial in patients with non-small cell lung cancer and in a Phase 2 study in patients with nasopharyngeal cancer... Cyclacel's Press Release -
